Treatment
Tenecteplase clinical trials
We’re tracking 40 recruiting studies that include Tenecteplase, each written for real people, not researchers, below.
Recruiting studies
- NCT07712445Recruiting
Testing a clot-busting drug coated with platelet membranes
This study tests a new way to deliver a clot-dissolving drug called tenecteplase. The drug is coated with platelet membranes to target blood clots in arteries. It may offer a safer, more effective treatment for heart attack patients and is also enrolling healthy volunteers for comparison.
Nanjing, JiangsuAges 18–75 - NCT06571149RecruitingPhase 4
Blood thinners and clot-busting drugs for stroke
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
EisenstadtAges 18 years+ - NCT03998319RecruitingPhase 3
Testing low-dose clot-busting drug after heart attack stent
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
Bankstown, New South WalesAges 18 years+ - NCT04201964Recruiting
TNK treatment for stroke when blood flow didn’t reopen enough
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
ShenyangAges 18 years+ - NCT05199662RecruitingPhase 3
IV clot-busting medicine for stroke when standard options don’t fit
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT05604638RecruitingPhase 3
Tirofiban soon after tenecteplase for acute stroke flare
This trial tests whether starting tirofiban soon after tenecteplase can improve outcomes for people whose stroke symptoms temporarily get worse after treatment. It aims to see if the added medicine can reduce harmful clot-related changes after initial thrombolysis.
Chuzhou, AnhuiAges 18 years+ - NCT06241677Recruiting
Clot-busting therapy for stroke patients on blood thinners
This study tests whether giving a clot-busting medicine through an IV can help people who have had a stroke while taking a common blood thinner (apixaban, dabigatran, edoxaban, or rivaroxaban). It may be an option if your last dose of the blood thinner was 12 to 48 hours before the stroke and you arrive at the hospital within 4.5 hours of symptoms starting.
Hong KongAges 18 years+ - NCT06320431RecruitingPhase 3
Clot-busting drug for disabling stroke within 4.5 hours
This trial tests a clot-busting drug called tenecteplase for people having a disabling ischemic stroke (a clot blocking blood flow to the brain). It aims to see if the drug can help improve recovery when given within 4.5 hours of symptoms starting.
Sydney, BarangarooAges 18 years+ - NCT06498323RecruitingPhase 4
Comparing TNK vs TPA for stroke in a mobile unit
This trial compares two clot-busting medicines, TNK and TPA, given through an IV in a special ambulance (Mobile Stroke Unit) to treat acute ischemic stroke. The goal is to see which drug works better when started quickly after symptoms begin.
BangkokAges 18 years+ - NCT06556446Recruiting
Clot-busting drug after stroke if on blood thinner
This study looks at whether giving a clot-busting medicine (IV thrombolysis) is safe and effective for people who have had a stroke and also recently took a direct oral anticoagulant (DOAC). If you've taken a DOAC in the last 48 hours, this trial may help doctors decide the best treatment for you.
InnsbruckAges 18 years+ - NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
Hefei, AnhuiAges 18 years+ - NCT06994975RecruitingPhase 3
Stroke drug test for patients who missed the 4.5 hour window
This trial tests a clot-busting drug for people who had a stroke more than 4.5 hours ago. It uses a special CT scan to see if the treatment can still help them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07094763Recruiting
Tenecteplase for posterior stroke 4.5-24 hours after onset
This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.
HefeiAges 18–100 - NCT07283159RecruitingPhase 2
Tenecteplase plus a second drug for stroke recovery
This study tests whether giving a second drug (urinary kallidinogenase) after the clot-busting drug tenecteplase can help people with moderate to severe ischemic strokes recover better. It is for patients who started treatment within 4.5 hours of symptoms.
ShenyangAges 18 years+ - NCT07302854RecruitingPhase 2/Phase 3
Clot-busting medicine for medium vessel strokes
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
Wuhan, HubeiAges 18 years+ - NCT07606807RecruitingPhase 3
New clot-busting medication for stroke in the extended time window
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
GuangzhouAges 18 years+
Common questions
- Are there clinical trials studying Tenecteplase?
- Yes. Clin2 currently lists 40 recruiting studies that include Tenecteplase, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tenecteplase trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tenecteplase an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tenecteplase or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.